Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults.

OBJECTIVE: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs.

METHODS: Prospective cohort study from the nationwide Danish Multiple Sclerosis Registry including all patients with a MS diagnosis who initiated treatment with an approved DMT before the age of 18 (N = 137) and followed until their 25th birthday. Selected baseline predictors were tested in univariate and multivariate regression models.

RESULTS: Multivariate analyses showed that being female and having disease duration for 2 or more years prior to DMT initiation predicted a higher relapse rate. In addition, disease duration and baseline expanded disability status scale (EDSS) predicted both confirmed disability worsening and improvement. We found no difference in treatment outcome between children with MS onset before and after the age of 13 years.

CONCLUSIONS: The efficacy of DMT in paediatric onset MS patients is comparable to that seen in adult onset MS patients. Earlier treatment start is associated with a beneficial prognosis in the paediatric cohort.

Original languageEnglish
JournalMultiple Sclerosis Journal
Volume26
Issue number8
Pages (from-to)964-975
Number of pages12
ISSN1352-4585
DOIs
Publication statusPublished - Jul 2020

ID: 61517142